Revenio Group Oyj reflects attractive technical aspects that could allow investors to expect a trend reversal over the medium term.
Strengths
● Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Analyst opinion has improved significantly over the past four months.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
● Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.02 times its estimated earnings per share for the ongoing year.
● Based on current prices, the company has particularly high valuation levels.
● The company appears highly valued given the size of its balance sheet.
● The valuation of the company is particularly high given the cash flows generated by its activity.
● The company is not the most generous with respect to shareholders' compensation.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
● For the past year, analysts have significantly revised downwards their profit estimates.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
● Over the past four months, analysts' average price target has been revised downwards significantly.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Companyâs activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.